ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Arcellx Inc

Arcellx Inc (ACLX)

54.41
-1.38
(-2.47%)
Closed June 15 4:00PM
54.41
0.00
(0.00%)
After Hours: 5:30PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
54.41
Bid
52.31
Ask
60.44
Volume
352,296
53.725 Day's Range 56.09
30.74 52 Week Range 75.10
Market Cap
Previous Close
55.79
Open
54.96
Last Trade
12
@
52.75
Last Trade Time
Financial Volume
$ 19,262,520
VWAP
54.6771
Average Volume (3m)
459,312
Shares Outstanding
52,796,618
Dividend Yield
-
PE Ratio
-40.64
Earnings Per Share (EPS)
-1.34
Revenue
110.32M
Net Profit
-70.69M

About Arcellx Inc

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcellx Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ACLX. The last closing price for Arcellx was $55.79. Over the last year, Arcellx shares have traded in a share price range of $ 30.74 to $ 75.10.

Arcellx currently has 52,796,618 shares outstanding. The market capitalization of Arcellx is $2.87 billion. Arcellx has a price to earnings ratio (PE ratio) of -40.64.

ACLX Latest News

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody...

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody...

Arcellx Provides First Quarter 2024 Financial Results

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.567.0009832841750.8558.6850.0248225254.41296355CS
41.482.7961458530152.9358.6849.9745366652.91079182CS
12-18.13-24.993107251272.5472.5447.8845931255.26490509CS
263.46.6653597333951.0175.147.8847560358.457959CS
5215.3539.29851510539.0675.130.7454735347.7511227CS
15635.41186.3684210531975.16.03547216836.89326909CS
26035.41186.3684210531975.16.03547216836.89326909CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

ACLX Discussion

View Posts
Monksdream Monksdream 2 months ago
ACLX over $30
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ACLX new 52 week high
👍️0
bandit007 bandit007 2 years ago
Going beast mode into next week.
👍️0
TheyWantYourShares TheyWantYourShares 2 years ago
Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


Got in on the drop @average: 13.12 … 2 and 3 days ago.


$ACLX


GLTA!!



-TWYS
👍️0
crudeoil24 crudeoil24 2 years ago
Net loss of $44M > no revenues! ( over 9 month period)

ACLX
👍️0
crudeoil24 crudeoil24 2 years ago
Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.
👍️0

Your Recent History

Delayed Upgrade Clock